nodes	percent_of_prediction	percent_of_DWPC	metapath
Ziprasidone—HTR2C—Sorafenib—liver cancer	0.11	0.254	CbGbCtD
Ziprasidone—CYP3A7—Sorafenib—liver cancer	0.0718	0.165	CbGbCtD
Ziprasidone—CYP3A7-CYP3A51P—Sorafenib—liver cancer	0.0718	0.165	CbGbCtD
Ziprasidone—CYP3A5—Sorafenib—liver cancer	0.0539	0.124	CbGbCtD
Ziprasidone—CYP1A2—Sorafenib—liver cancer	0.0401	0.0923	CbGbCtD
Ziprasidone—CYP2D6—Sorafenib—liver cancer	0.033	0.076	CbGbCtD
Ziprasidone—CYP3A4—Sorafenib—liver cancer	0.021	0.0483	CbGbCtD
Ziprasidone—CYP2D6—Doxorubicin—liver cancer	0.02	0.0461	CbGbCtD
Ziprasidone—CYP3A4—Doxorubicin—liver cancer	0.0127	0.0293	CbGbCtD
Ziprasidone—Diabetes mellitus—Doxorubicin—liver cancer	0.000539	0.00142	CcSEcCtD
Ziprasidone—Dermatitis exfoliative—Epirubicin—liver cancer	0.000537	0.00141	CcSEcCtD
Ziprasidone—Urticaria—Sorafenib—liver cancer	0.000535	0.00141	CcSEcCtD
Ziprasidone—Body temperature increased—Sorafenib—liver cancer	0.000533	0.0014	CcSEcCtD
Ziprasidone—Abdominal pain—Sorafenib—liver cancer	0.000533	0.0014	CcSEcCtD
Ziprasidone—Renal impairment—Epirubicin—liver cancer	0.000532	0.0014	CcSEcCtD
Ziprasidone—Dermatitis bullous—Epirubicin—liver cancer	0.00053	0.00139	CcSEcCtD
Ziprasidone—Eczema—Doxorubicin—liver cancer	0.000522	0.00137	CcSEcCtD
Ziprasidone—Hypoglycaemia—Epirubicin—liver cancer	0.000519	0.00136	CcSEcCtD
Ziprasidone—Lethargy—Epirubicin—liver cancer	0.000517	0.00136	CcSEcCtD
Ziprasidone—Cerebrovascular accident—Epirubicin—liver cancer	0.000517	0.00136	CcSEcCtD
Ziprasidone—Hyponatraemia—Epirubicin—liver cancer	0.000509	0.00134	CcSEcCtD
Ziprasidone—Renal failure acute—Doxorubicin—liver cancer	0.000508	0.00133	CcSEcCtD
Ziprasidone—Pain in extremity—Epirubicin—liver cancer	0.000507	0.00133	CcSEcCtD
Ziprasidone—Osteoarthritis—Epirubicin—liver cancer	0.000507	0.00133	CcSEcCtD
Ziprasidone—Diplopia—Epirubicin—liver cancer	0.000507	0.00133	CcSEcCtD
Ziprasidone—Increased appetite—Doxorubicin—liver cancer	0.000499	0.00131	CcSEcCtD
Ziprasidone—Dermatitis exfoliative—Doxorubicin—liver cancer	0.000497	0.00131	CcSEcCtD
Ziprasidone—Hypersensitivity—Sorafenib—liver cancer	0.000496	0.00131	CcSEcCtD
Ziprasidone—Renal impairment—Doxorubicin—liver cancer	0.000493	0.00129	CcSEcCtD
Ziprasidone—Dermatitis bullous—Doxorubicin—liver cancer	0.00049	0.00129	CcSEcCtD
Ziprasidone—Face oedema—Epirubicin—liver cancer	0.000489	0.00129	CcSEcCtD
Ziprasidone—Asthenia—Sorafenib—liver cancer	0.000483	0.00127	CcSEcCtD
Ziprasidone—Hypoglycaemia—Doxorubicin—liver cancer	0.00048	0.00126	CcSEcCtD
Ziprasidone—Lethargy—Doxorubicin—liver cancer	0.000478	0.00126	CcSEcCtD
Ziprasidone—Cerebrovascular accident—Doxorubicin—liver cancer	0.000478	0.00126	CcSEcCtD
Ziprasidone—Ataxia—Epirubicin—liver cancer	0.000476	0.00125	CcSEcCtD
Ziprasidone—Blood creatinine increased—Epirubicin—liver cancer	0.000475	0.00125	CcSEcCtD
Ziprasidone—Dehydration—Epirubicin—liver cancer	0.000471	0.00124	CcSEcCtD
Ziprasidone—Hyponatraemia—Doxorubicin—liver cancer	0.000471	0.00124	CcSEcCtD
Ziprasidone—Diplopia—Doxorubicin—liver cancer	0.000469	0.00123	CcSEcCtD
Ziprasidone—Osteoarthritis—Doxorubicin—liver cancer	0.000469	0.00123	CcSEcCtD
Ziprasidone—Pain in extremity—Doxorubicin—liver cancer	0.000469	0.00123	CcSEcCtD
Ziprasidone—Liver function test abnormal—Epirubicin—liver cancer	0.000468	0.00123	CcSEcCtD
Ziprasidone—Orthostatic hypotension—Epirubicin—liver cancer	0.000463	0.00122	CcSEcCtD
Ziprasidone—Hypokalaemia—Epirubicin—liver cancer	0.000461	0.00121	CcSEcCtD
Ziprasidone—Diarrhoea—Sorafenib—liver cancer	0.000461	0.00121	CcSEcCtD
Ziprasidone—Breast disorder—Epirubicin—liver cancer	0.000458	0.0012	CcSEcCtD
Ziprasidone—Nasopharyngitis—Epirubicin—liver cancer	0.000453	0.00119	CcSEcCtD
Ziprasidone—Face oedema—Doxorubicin—liver cancer	0.000453	0.00119	CcSEcCtD
Ziprasidone—Gastritis—Epirubicin—liver cancer	0.000448	0.00118	CcSEcCtD
Ziprasidone—Dizziness—Sorafenib—liver cancer	0.000446	0.00117	CcSEcCtD
Ziprasidone—Ataxia—Doxorubicin—liver cancer	0.000441	0.00116	CcSEcCtD
Ziprasidone—Blood creatinine increased—Doxorubicin—liver cancer	0.000439	0.00115	CcSEcCtD
Ziprasidone—Dysphagia—Epirubicin—liver cancer	0.000438	0.00115	CcSEcCtD
Ziprasidone—Influenza—Epirubicin—liver cancer	0.000438	0.00115	CcSEcCtD
Ziprasidone—Dehydration—Doxorubicin—liver cancer	0.000436	0.00115	CcSEcCtD
Ziprasidone—Eosinophilia—Epirubicin—liver cancer	0.000434	0.00114	CcSEcCtD
Ziprasidone—Liver function test abnormal—Doxorubicin—liver cancer	0.000433	0.00114	CcSEcCtD
Ziprasidone—Vomiting—Sorafenib—liver cancer	0.000428	0.00113	CcSEcCtD
Ziprasidone—Orthostatic hypotension—Doxorubicin—liver cancer	0.000428	0.00113	CcSEcCtD
Ziprasidone—Hypokalaemia—Doxorubicin—liver cancer	0.000427	0.00112	CcSEcCtD
Ziprasidone—Angina pectoris—Epirubicin—liver cancer	0.000427	0.00112	CcSEcCtD
Ziprasidone—Rash—Sorafenib—liver cancer	0.000425	0.00112	CcSEcCtD
Ziprasidone—Dermatitis—Sorafenib—liver cancer	0.000424	0.00112	CcSEcCtD
Ziprasidone—Breast disorder—Doxorubicin—liver cancer	0.000424	0.00111	CcSEcCtD
Ziprasidone—Headache—Sorafenib—liver cancer	0.000422	0.00111	CcSEcCtD
Ziprasidone—Nasopharyngitis—Doxorubicin—liver cancer	0.000419	0.0011	CcSEcCtD
Ziprasidone—Gastritis—Doxorubicin—liver cancer	0.000415	0.00109	CcSEcCtD
Ziprasidone—Dysuria—Epirubicin—liver cancer	0.000409	0.00108	CcSEcCtD
Ziprasidone—Upper respiratory tract infection—Epirubicin—liver cancer	0.000407	0.00107	CcSEcCtD
Ziprasidone—Dysphagia—Doxorubicin—liver cancer	0.000405	0.00107	CcSEcCtD
Ziprasidone—Influenza—Doxorubicin—liver cancer	0.000405	0.00107	CcSEcCtD
Ziprasidone—Eosinophilia—Doxorubicin—liver cancer	0.000401	0.00105	CcSEcCtD
Ziprasidone—Nausea—Sorafenib—liver cancer	0.0004	0.00105	CcSEcCtD
Ziprasidone—Photosensitivity reaction—Epirubicin—liver cancer	0.0004	0.00105	CcSEcCtD
Ziprasidone—Weight increased—Epirubicin—liver cancer	0.000398	0.00105	CcSEcCtD
Ziprasidone—Weight decreased—Epirubicin—liver cancer	0.000396	0.00104	CcSEcCtD
Ziprasidone—Hyperglycaemia—Epirubicin—liver cancer	0.000395	0.00104	CcSEcCtD
Ziprasidone—Angina pectoris—Doxorubicin—liver cancer	0.000395	0.00104	CcSEcCtD
Ziprasidone—Pneumonia—Epirubicin—liver cancer	0.000393	0.00103	CcSEcCtD
Ziprasidone—Infestation NOS—Epirubicin—liver cancer	0.00039	0.00103	CcSEcCtD
Ziprasidone—Infestation—Epirubicin—liver cancer	0.00039	0.00103	CcSEcCtD
Ziprasidone—Renal failure—Epirubicin—liver cancer	0.000384	0.00101	CcSEcCtD
Ziprasidone—Neuropathy peripheral—Epirubicin—liver cancer	0.000383	0.00101	CcSEcCtD
Ziprasidone—Jaundice—Epirubicin—liver cancer	0.000381	0.001	CcSEcCtD
Ziprasidone—Conjunctivitis—Epirubicin—liver cancer	0.000379	0.000998	CcSEcCtD
Ziprasidone—Dysuria—Doxorubicin—liver cancer	0.000379	0.000996	CcSEcCtD
Ziprasidone—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000377	0.00099	CcSEcCtD
Ziprasidone—Sweating—Epirubicin—liver cancer	0.000374	0.000984	CcSEcCtD
Ziprasidone—Haematuria—Epirubicin—liver cancer	0.000372	0.000979	CcSEcCtD
Ziprasidone—Photosensitivity reaction—Doxorubicin—liver cancer	0.00037	0.000972	CcSEcCtD
Ziprasidone—Weight increased—Doxorubicin—liver cancer	0.000369	0.000969	CcSEcCtD
Ziprasidone—Epistaxis—Epirubicin—liver cancer	0.000368	0.000968	CcSEcCtD
Ziprasidone—Weight decreased—Doxorubicin—liver cancer	0.000367	0.000964	CcSEcCtD
Ziprasidone—Hyperglycaemia—Doxorubicin—liver cancer	0.000365	0.000961	CcSEcCtD
Ziprasidone—Pneumonia—Doxorubicin—liver cancer	0.000363	0.000955	CcSEcCtD
Ziprasidone—Infestation NOS—Doxorubicin—liver cancer	0.000361	0.00095	CcSEcCtD
Ziprasidone—Infestation—Doxorubicin—liver cancer	0.000361	0.00095	CcSEcCtD
Ziprasidone—Bradycardia—Epirubicin—liver cancer	0.000357	0.000938	CcSEcCtD
Ziprasidone—Renal failure—Doxorubicin—liver cancer	0.000355	0.000934	CcSEcCtD
Ziprasidone—Neuropathy peripheral—Doxorubicin—liver cancer	0.000354	0.000931	CcSEcCtD
Ziprasidone—Haemoglobin—Epirubicin—liver cancer	0.000352	0.000926	CcSEcCtD
Ziprasidone—Jaundice—Doxorubicin—liver cancer	0.000352	0.000926	CcSEcCtD
Ziprasidone—Rhinitis—Epirubicin—liver cancer	0.000351	0.000924	CcSEcCtD
Ziprasidone—Conjunctivitis—Doxorubicin—liver cancer	0.000351	0.000923	CcSEcCtD
Ziprasidone—Haemorrhage—Epirubicin—liver cancer	0.00035	0.000921	CcSEcCtD
Ziprasidone—Hepatitis—Epirubicin—liver cancer	0.00035	0.000921	CcSEcCtD
Ziprasidone—Hypoaesthesia—Epirubicin—liver cancer	0.000349	0.000917	CcSEcCtD
Ziprasidone—Pharyngitis—Epirubicin—liver cancer	0.000348	0.000915	CcSEcCtD
Ziprasidone—Sweating—Doxorubicin—liver cancer	0.000346	0.00091	CcSEcCtD
Ziprasidone—Urinary tract disorder—Epirubicin—liver cancer	0.000346	0.00091	CcSEcCtD
Ziprasidone—Oedema peripheral—Epirubicin—liver cancer	0.000345	0.000908	CcSEcCtD
Ziprasidone—Haematuria—Doxorubicin—liver cancer	0.000344	0.000906	CcSEcCtD
Ziprasidone—Connective tissue disorder—Epirubicin—liver cancer	0.000344	0.000905	CcSEcCtD
Ziprasidone—Urethral disorder—Epirubicin—liver cancer	0.000344	0.000903	CcSEcCtD
Ziprasidone—Epistaxis—Doxorubicin—liver cancer	0.000341	0.000896	CcSEcCtD
Ziprasidone—Visual impairment—Epirubicin—liver cancer	0.000338	0.000888	CcSEcCtD
Ziprasidone—Bradycardia—Doxorubicin—liver cancer	0.00033	0.000868	CcSEcCtD
Ziprasidone—Eye disorder—Epirubicin—liver cancer	0.000328	0.000861	CcSEcCtD
Ziprasidone—Tinnitus—Epirubicin—liver cancer	0.000327	0.000859	CcSEcCtD
Ziprasidone—Haemoglobin—Doxorubicin—liver cancer	0.000326	0.000857	CcSEcCtD
Ziprasidone—Cardiac disorder—Epirubicin—liver cancer	0.000325	0.000855	CcSEcCtD
Ziprasidone—Rhinitis—Doxorubicin—liver cancer	0.000325	0.000855	CcSEcCtD
Ziprasidone—Haemorrhage—Doxorubicin—liver cancer	0.000324	0.000853	CcSEcCtD
Ziprasidone—Hepatitis—Doxorubicin—liver cancer	0.000324	0.000853	CcSEcCtD
Ziprasidone—Hypoaesthesia—Doxorubicin—liver cancer	0.000323	0.000848	CcSEcCtD
Ziprasidone—Pharyngitis—Doxorubicin—liver cancer	0.000322	0.000846	CcSEcCtD
Ziprasidone—Urinary tract disorder—Doxorubicin—liver cancer	0.00032	0.000842	CcSEcCtD
Ziprasidone—Oedema peripheral—Doxorubicin—liver cancer	0.000319	0.00084	CcSEcCtD
Ziprasidone—Connective tissue disorder—Doxorubicin—liver cancer	0.000319	0.000838	CcSEcCtD
Ziprasidone—Angiopathy—Epirubicin—liver cancer	0.000318	0.000836	CcSEcCtD
Ziprasidone—Urethral disorder—Doxorubicin—liver cancer	0.000318	0.000836	CcSEcCtD
Ziprasidone—Immune system disorder—Epirubicin—liver cancer	0.000317	0.000832	CcSEcCtD
Ziprasidone—Mediastinal disorder—Epirubicin—liver cancer	0.000316	0.00083	CcSEcCtD
Ziprasidone—Chills—Epirubicin—liver cancer	0.000314	0.000827	CcSEcCtD
Ziprasidone—Arrhythmia—Epirubicin—liver cancer	0.000313	0.000823	CcSEcCtD
Ziprasidone—Visual impairment—Doxorubicin—liver cancer	0.000313	0.000822	CcSEcCtD
Ziprasidone—Alopecia—Epirubicin—liver cancer	0.00031	0.000814	CcSEcCtD
Ziprasidone—Mental disorder—Epirubicin—liver cancer	0.000307	0.000807	CcSEcCtD
Ziprasidone—Malnutrition—Epirubicin—liver cancer	0.000305	0.000802	CcSEcCtD
Ziprasidone—Erythema—Epirubicin—liver cancer	0.000305	0.000802	CcSEcCtD
Ziprasidone—Eye disorder—Doxorubicin—liver cancer	0.000303	0.000797	CcSEcCtD
Ziprasidone—Tinnitus—Doxorubicin—liver cancer	0.000302	0.000795	CcSEcCtD
Ziprasidone—Cardiac disorder—Doxorubicin—liver cancer	0.000301	0.000791	CcSEcCtD
Ziprasidone—Flatulence—Epirubicin—liver cancer	0.000301	0.00079	CcSEcCtD
Ziprasidone—Back pain—Epirubicin—liver cancer	0.000295	0.000776	CcSEcCtD
Ziprasidone—Angiopathy—Doxorubicin—liver cancer	0.000294	0.000774	CcSEcCtD
Ziprasidone—Muscle spasms—Epirubicin—liver cancer	0.000293	0.000771	CcSEcCtD
Ziprasidone—Immune system disorder—Doxorubicin—liver cancer	0.000293	0.00077	CcSEcCtD
Ziprasidone—Mediastinal disorder—Doxorubicin—liver cancer	0.000292	0.000768	CcSEcCtD
Ziprasidone—Chills—Doxorubicin—liver cancer	0.000291	0.000765	CcSEcCtD
Ziprasidone—Arrhythmia—Doxorubicin—liver cancer	0.00029	0.000762	CcSEcCtD
Ziprasidone—Vision blurred—Epirubicin—liver cancer	0.000288	0.000756	CcSEcCtD
Ziprasidone—Alopecia—Doxorubicin—liver cancer	0.000287	0.000753	CcSEcCtD
Ziprasidone—Mental disorder—Doxorubicin—liver cancer	0.000284	0.000747	CcSEcCtD
Ziprasidone—Malnutrition—Doxorubicin—liver cancer	0.000282	0.000742	CcSEcCtD
Ziprasidone—Erythema—Doxorubicin—liver cancer	0.000282	0.000742	CcSEcCtD
Ziprasidone—Anaemia—Epirubicin—liver cancer	0.000282	0.000741	CcSEcCtD
Ziprasidone—Agitation—Epirubicin—liver cancer	0.00028	0.000737	CcSEcCtD
Ziprasidone—Flatulence—Doxorubicin—liver cancer	0.000278	0.000731	CcSEcCtD
Ziprasidone—Vertigo—Epirubicin—liver cancer	0.000274	0.000721	CcSEcCtD
Ziprasidone—Syncope—Epirubicin—liver cancer	0.000274	0.000719	CcSEcCtD
Ziprasidone—Leukopenia—Epirubicin—liver cancer	0.000273	0.000718	CcSEcCtD
Ziprasidone—Back pain—Doxorubicin—liver cancer	0.000273	0.000718	CcSEcCtD
Ziprasidone—Muscle spasms—Doxorubicin—liver cancer	0.000271	0.000714	CcSEcCtD
Ziprasidone—Palpitations—Epirubicin—liver cancer	0.00027	0.000709	CcSEcCtD
Ziprasidone—Loss of consciousness—Epirubicin—liver cancer	0.000268	0.000705	CcSEcCtD
Ziprasidone—Cough—Epirubicin—liver cancer	0.000266	0.0007	CcSEcCtD
Ziprasidone—Vision blurred—Doxorubicin—liver cancer	0.000266	0.000699	CcSEcCtD
Ziprasidone—Hypertension—Epirubicin—liver cancer	0.000263	0.000693	CcSEcCtD
Ziprasidone—Anaemia—Doxorubicin—liver cancer	0.000261	0.000686	CcSEcCtD
Ziprasidone—Chest pain—Epirubicin—liver cancer	0.00026	0.000683	CcSEcCtD
Ziprasidone—Arthralgia—Epirubicin—liver cancer	0.00026	0.000683	CcSEcCtD
Ziprasidone—Myalgia—Epirubicin—liver cancer	0.00026	0.000683	CcSEcCtD
Ziprasidone—Agitation—Doxorubicin—liver cancer	0.000259	0.000682	CcSEcCtD
Ziprasidone—Anxiety—Epirubicin—liver cancer	0.000259	0.000681	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000258	0.000678	CcSEcCtD
Ziprasidone—Dry mouth—Epirubicin—liver cancer	0.000254	0.000668	CcSEcCtD
Ziprasidone—Vertigo—Doxorubicin—liver cancer	0.000254	0.000667	CcSEcCtD
Ziprasidone—Syncope—Doxorubicin—liver cancer	0.000253	0.000666	CcSEcCtD
Ziprasidone—Leukopenia—Doxorubicin—liver cancer	0.000253	0.000664	CcSEcCtD
Ziprasidone—Confusional state—Epirubicin—liver cancer	0.000251	0.00066	CcSEcCtD
Ziprasidone—Palpitations—Doxorubicin—liver cancer	0.000249	0.000656	CcSEcCtD
Ziprasidone—Loss of consciousness—Doxorubicin—liver cancer	0.000248	0.000652	CcSEcCtD
Ziprasidone—Infection—Epirubicin—liver cancer	0.000247	0.00065	CcSEcCtD
Ziprasidone—Cough—Doxorubicin—liver cancer	0.000246	0.000648	CcSEcCtD
Ziprasidone—Shock—Epirubicin—liver cancer	0.000245	0.000644	CcSEcCtD
Ziprasidone—Nervous system disorder—Epirubicin—liver cancer	0.000244	0.000642	CcSEcCtD
Ziprasidone—Thrombocytopenia—Epirubicin—liver cancer	0.000244	0.000641	CcSEcCtD
Ziprasidone—Hypertension—Doxorubicin—liver cancer	0.000244	0.000641	CcSEcCtD
Ziprasidone—Tachycardia—Epirubicin—liver cancer	0.000243	0.000639	CcSEcCtD
Ziprasidone—Skin disorder—Epirubicin—liver cancer	0.000242	0.000636	CcSEcCtD
Ziprasidone—Hyperhidrosis—Epirubicin—liver cancer	0.000241	0.000633	CcSEcCtD
Ziprasidone—Myalgia—Doxorubicin—liver cancer	0.00024	0.000632	CcSEcCtD
Ziprasidone—Chest pain—Doxorubicin—liver cancer	0.00024	0.000632	CcSEcCtD
Ziprasidone—Arthralgia—Doxorubicin—liver cancer	0.00024	0.000632	CcSEcCtD
Ziprasidone—Anxiety—Doxorubicin—liver cancer	0.00024	0.00063	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000239	0.000628	CcSEcCtD
Ziprasidone—Anorexia—Epirubicin—liver cancer	0.000237	0.000624	CcSEcCtD
Ziprasidone—Dry mouth—Doxorubicin—liver cancer	0.000235	0.000618	CcSEcCtD
Ziprasidone—Hypotension—Epirubicin—liver cancer	0.000233	0.000612	CcSEcCtD
Ziprasidone—Confusional state—Doxorubicin—liver cancer	0.000232	0.000611	CcSEcCtD
Ziprasidone—Infection—Doxorubicin—liver cancer	0.000229	0.000602	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000227	0.000596	CcSEcCtD
Ziprasidone—Shock—Doxorubicin—liver cancer	0.000227	0.000596	CcSEcCtD
Ziprasidone—Nervous system disorder—Doxorubicin—liver cancer	0.000226	0.000594	CcSEcCtD
Ziprasidone—Thrombocytopenia—Doxorubicin—liver cancer	0.000226	0.000593	CcSEcCtD
Ziprasidone—Insomnia—Epirubicin—liver cancer	0.000225	0.000592	CcSEcCtD
Ziprasidone—Tachycardia—Doxorubicin—liver cancer	0.000225	0.000591	CcSEcCtD
Ziprasidone—Skin disorder—Doxorubicin—liver cancer	0.000224	0.000588	CcSEcCtD
Ziprasidone—Paraesthesia—Epirubicin—liver cancer	0.000224	0.000588	CcSEcCtD
Ziprasidone—Hyperhidrosis—Doxorubicin—liver cancer	0.000223	0.000586	CcSEcCtD
Ziprasidone—Dyspnoea—Epirubicin—liver cancer	0.000222	0.000584	CcSEcCtD
Ziprasidone—Somnolence—Epirubicin—liver cancer	0.000221	0.000582	CcSEcCtD
Ziprasidone—Anorexia—Doxorubicin—liver cancer	0.00022	0.000577	CcSEcCtD
Ziprasidone—Dyspepsia—Epirubicin—liver cancer	0.000219	0.000576	CcSEcCtD
Ziprasidone—Decreased appetite—Epirubicin—liver cancer	0.000216	0.000569	CcSEcCtD
Ziprasidone—Hypotension—Doxorubicin—liver cancer	0.000215	0.000566	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Epirubicin—liver cancer	0.000215	0.000565	CcSEcCtD
Ziprasidone—Fatigue—Epirubicin—liver cancer	0.000215	0.000564	CcSEcCtD
Ziprasidone—Constipation—Epirubicin—liver cancer	0.000213	0.00056	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00021	0.000552	CcSEcCtD
Ziprasidone—Insomnia—Doxorubicin—liver cancer	0.000208	0.000548	CcSEcCtD
Ziprasidone—Paraesthesia—Doxorubicin—liver cancer	0.000207	0.000544	CcSEcCtD
Ziprasidone—Dyspnoea—Doxorubicin—liver cancer	0.000205	0.00054	CcSEcCtD
Ziprasidone—Feeling abnormal—Epirubicin—liver cancer	0.000205	0.000539	CcSEcCtD
Ziprasidone—Somnolence—Doxorubicin—liver cancer	0.000205	0.000538	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Epirubicin—liver cancer	0.000204	0.000535	CcSEcCtD
Ziprasidone—Dyspepsia—Doxorubicin—liver cancer	0.000203	0.000533	CcSEcCtD
Ziprasidone—Decreased appetite—Doxorubicin—liver cancer	0.0002	0.000527	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000199	0.000523	CcSEcCtD
Ziprasidone—Fatigue—Doxorubicin—liver cancer	0.000199	0.000522	CcSEcCtD
Ziprasidone—Urticaria—Epirubicin—liver cancer	0.000198	0.00052	CcSEcCtD
Ziprasidone—Constipation—Doxorubicin—liver cancer	0.000197	0.000518	CcSEcCtD
Ziprasidone—Body temperature increased—Epirubicin—liver cancer	0.000197	0.000518	CcSEcCtD
Ziprasidone—Abdominal pain—Epirubicin—liver cancer	0.000197	0.000518	CcSEcCtD
Ziprasidone—Feeling abnormal—Doxorubicin—liver cancer	0.00019	0.000499	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Doxorubicin—liver cancer	0.000188	0.000495	CcSEcCtD
Ziprasidone—Hypersensitivity—Epirubicin—liver cancer	0.000183	0.000482	CcSEcCtD
Ziprasidone—Urticaria—Doxorubicin—liver cancer	0.000183	0.000481	CcSEcCtD
Ziprasidone—Abdominal pain—Doxorubicin—liver cancer	0.000182	0.000479	CcSEcCtD
Ziprasidone—Body temperature increased—Doxorubicin—liver cancer	0.000182	0.000479	CcSEcCtD
Ziprasidone—Asthenia—Epirubicin—liver cancer	0.000179	0.00047	CcSEcCtD
Ziprasidone—Diarrhoea—Epirubicin—liver cancer	0.00017	0.000448	CcSEcCtD
Ziprasidone—Hypersensitivity—Doxorubicin—liver cancer	0.00017	0.000446	CcSEcCtD
Ziprasidone—Asthenia—Doxorubicin—liver cancer	0.000165	0.000435	CcSEcCtD
Ziprasidone—Dizziness—Epirubicin—liver cancer	0.000165	0.000433	CcSEcCtD
Ziprasidone—Vomiting—Epirubicin—liver cancer	0.000158	0.000416	CcSEcCtD
Ziprasidone—Diarrhoea—Doxorubicin—liver cancer	0.000158	0.000414	CcSEcCtD
Ziprasidone—Rash—Epirubicin—liver cancer	0.000157	0.000413	CcSEcCtD
Ziprasidone—Dermatitis—Epirubicin—liver cancer	0.000157	0.000412	CcSEcCtD
Ziprasidone—Headache—Epirubicin—liver cancer	0.000156	0.00041	CcSEcCtD
Ziprasidone—Dizziness—Doxorubicin—liver cancer	0.000152	0.000401	CcSEcCtD
Ziprasidone—Nausea—Epirubicin—liver cancer	0.000148	0.000389	CcSEcCtD
Ziprasidone—Vomiting—Doxorubicin—liver cancer	0.000146	0.000385	CcSEcCtD
Ziprasidone—Rash—Doxorubicin—liver cancer	0.000145	0.000382	CcSEcCtD
Ziprasidone—Dermatitis—Doxorubicin—liver cancer	0.000145	0.000382	CcSEcCtD
Ziprasidone—Headache—Doxorubicin—liver cancer	0.000144	0.000379	CcSEcCtD
Ziprasidone—Nausea—Doxorubicin—liver cancer	0.000137	0.00036	CcSEcCtD
Ziprasidone—CHRM1—Signaling Pathways—JUN—liver cancer	6.94e-06	3.75e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CCND1—liver cancer	6.94e-06	3.75e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CTNNB1—liver cancer	6.93e-06	3.75e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—GSTP1—liver cancer	6.93e-06	3.75e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—JUN—liver cancer	6.92e-06	3.74e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CTNNB1—liver cancer	6.91e-06	3.74e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—MMP9—liver cancer	6.9e-06	3.73e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—HRAS—liver cancer	6.89e-06	3.73e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CTNNB1—liver cancer	6.89e-06	3.73e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—TP53—liver cancer	6.89e-06	3.73e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—KRAS—liver cancer	6.89e-06	3.72e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—HRAS—liver cancer	6.88e-06	3.72e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CDKN1A—liver cancer	6.88e-06	3.72e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CCND1—liver cancer	6.87e-06	3.71e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CTNNB1—liver cancer	6.87e-06	3.71e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—JUN—liver cancer	6.85e-06	3.71e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CCND1—liver cancer	6.85e-06	3.7e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—HRAS—liver cancer	6.84e-06	3.7e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—JUN—liver cancer	6.84e-06	3.7e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—HMOX1—liver cancer	6.83e-06	3.69e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—VEGFA—liver cancer	6.83e-06	3.69e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CTNNB1—liver cancer	6.8e-06	3.68e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—TP53—liver cancer	6.8e-06	3.68e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—MMP9—liver cancer	6.79e-06	3.67e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—HRAS—liver cancer	6.79e-06	3.67e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CTNNB1—liver cancer	6.78e-06	3.67e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—MMP9—liver cancer	6.78e-06	3.66e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CDKN1A—liver cancer	6.77e-06	3.66e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—STAT3—liver cancer	6.76e-06	3.66e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—MMP9—liver cancer	6.76e-06	3.65e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CDKN1A—liver cancer	6.75e-06	3.65e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—MMP9—liver cancer	6.73e-06	3.64e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CDKN1A—liver cancer	6.73e-06	3.64e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—PIK3CA—liver cancer	6.73e-06	3.64e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—MYC—liver cancer	6.73e-06	3.64e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—VEGFA—liver cancer	6.72e-06	3.64e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—MAPK8—liver cancer	6.71e-06	3.63e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—TGFB1—liver cancer	6.71e-06	3.63e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CDKN1A—liver cancer	6.71e-06	3.63e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—HRAS—liver cancer	6.7e-06	3.62e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—AKT1—liver cancer	6.69e-06	3.62e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CDKN1B—liver cancer	6.67e-06	3.61e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MMP9—liver cancer	6.67e-06	3.61e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—STAT3—liver cancer	6.66e-06	3.6e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MMP9—liver cancer	6.65e-06	3.6e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CDKN1A—liver cancer	6.64e-06	3.59e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CDKN1A—liver cancer	6.63e-06	3.58e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—MAPK8—liver cancer	6.61e-06	3.57e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—GPCR downstream signaling—AKT1—liver cancer	6.6e-06	3.57e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—IL6—liver cancer	6.6e-06	3.57e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—MAPK8—liver cancer	6.59e-06	3.56e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—HRAS—liver cancer	6.59e-06	3.56e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—IL6—liver cancer	6.59e-06	3.56e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—AKT1—liver cancer	6.59e-06	3.56e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—AKT1—liver cancer	6.57e-06	3.55e-05	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—PIK3CA—liver cancer	6.57e-06	3.55e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—MAPK8—liver cancer	6.57e-06	3.55e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—AKT1—liver cancer	6.55e-06	3.54e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—MAPK8—liver cancer	6.55e-06	3.54e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—IL6—liver cancer	6.55e-06	3.54e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CASP3—liver cancer	6.54e-06	3.54e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—AKT1—liver cancer	6.53e-06	3.53e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—IL2—liver cancer	6.53e-06	3.53e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—TP53—liver cancer	6.51e-06	3.52e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—HRAS—liver cancer	6.5e-06	3.52e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—IL6—liver cancer	6.5e-06	3.51e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—MYC—liver cancer	6.5e-06	3.51e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MAPK8—liver cancer	6.49e-06	3.51e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—TGFB1—liver cancer	6.48e-06	3.5e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—AKT1—liver cancer	6.47e-06	3.5e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MAPK8—liver cancer	6.47e-06	3.5e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—MYC—liver cancer	6.46e-06	3.49e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—AKT1—liver cancer	6.45e-06	3.49e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—TGFB1—liver cancer	6.45e-06	3.49e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	6.42e-06	3.47e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—PIK3CA—liver cancer	6.41e-06	3.47e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—IL6—liver cancer	6.41e-06	3.47e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—PIK3CA—liver cancer	6.38e-06	3.45e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—GSTM1—liver cancer	6.37e-06	3.44e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CCND1—liver cancer	6.36e-06	3.44e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PIK3CD—liver cancer	6.36e-06	3.44e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—JUN—liver cancer	6.35e-06	3.43e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—PIK3CA—liver cancer	6.33e-06	3.42e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—IL6—liver cancer	6.31e-06	3.41e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CTNNB1—liver cancer	6.3e-06	3.41e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—MYC—liver cancer	6.29e-06	3.4e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—ALB—liver cancer	6.27e-06	3.39e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—TGFB1—liver cancer	6.27e-06	3.39e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—HRAS—liver cancer	6.23e-06	3.37e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—IL6—liver cancer	6.22e-06	3.36e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—KRAS—liver cancer	6.22e-06	3.36e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—TP53—liver cancer	6.2e-06	3.35e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—VEGFA—liver cancer	6.2e-06	3.35e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—MYC—liver cancer	6.19e-06	3.34e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MMP9—liver cancer	6.18e-06	3.34e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—TGFB1—liver cancer	6.17e-06	3.34e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CDKN1A—liver cancer	6.16e-06	3.33e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—STAT3—liver cancer	6.14e-06	3.32e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PIK3CG—liver cancer	6.13e-06	3.31e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—TP53—liver cancer	6.12e-06	3.31e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—VEGFA—liver cancer	6.1e-06	3.3e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—VEGFA—liver cancer	6.09e-06	3.29e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—AKT1—liver cancer	6.09e-06	3.29e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—AKT1—liver cancer	6.08e-06	3.29e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—VEGFA—liver cancer	6.07e-06	3.28e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—VEGFA—liver cancer	6.05e-06	3.27e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—AKT1—liver cancer	6.04e-06	3.27e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—STAT3—liver cancer	6.04e-06	3.27e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—CYP1A1—liver cancer	6.04e-06	3.26e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—STAT3—liver cancer	6.03e-06	3.26e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MAPK8—liver cancer	6.01e-06	3.25e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—STAT3—liver cancer	6.01e-06	3.25e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—KRAS—liver cancer	6e-06	3.25e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—AKT1—liver cancer	5.99e-06	3.24e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—VEGFA—liver cancer	5.99e-06	3.24e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—STAT3—liver cancer	5.99e-06	3.24e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—VEGFA—liver cancer	5.97e-06	3.23e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—KRAS—liver cancer	5.97e-06	3.23e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—IL6—liver cancer	5.96e-06	3.22e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—HRAS—liver cancer	5.93e-06	3.21e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—STAT3—liver cancer	5.93e-06	3.21e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—STAT3—liver cancer	5.91e-06	3.2e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—AKT1—liver cancer	5.91e-06	3.2e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PPARG—liver cancer	5.91e-06	3.2e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—HRAS—liver cancer	5.85e-06	3.17e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—AKT1—liver cancer	5.82e-06	3.15e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—KRAS—liver cancer	5.81e-06	3.14e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—AKT1—liver cancer	5.74e-06	3.1e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—KRAS—liver cancer	5.72e-06	3.09e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—PIK3CA—liver cancer	5.71e-06	3.09e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—MYC—liver cancer	5.7e-06	3.08e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—TGFB1—liver cancer	5.69e-06	3.08e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—IL6—liver cancer	5.68e-06	3.07e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—PIK3CA—liver cancer	5.65e-06	3.05e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—MTHFR—liver cancer	5.63e-06	3.04e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—MYC—liver cancer	5.61e-06	3.03e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—IL6—liver cancer	5.6e-06	3.03e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—MYC—liver cancer	5.6e-06	3.03e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—TGFB1—liver cancer	5.6e-06	3.03e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—TGFB1—liver cancer	5.59e-06	3.02e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—MYC—liver cancer	5.58e-06	3.02e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—TGFB1—liver cancer	5.57e-06	3.01e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—MYC—liver cancer	5.56e-06	3.01e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—TGFB1—liver cancer	5.55e-06	3e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—VEGFA—liver cancer	5.55e-06	3e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PIK3CB—liver cancer	5.54e-06	3e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—TP53—liver cancer	5.53e-06	2.99e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PPARA—liver cancer	5.52e-06	2.98e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—PIK3CA—liver cancer	5.51e-06	2.98e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MYC—liver cancer	5.51e-06	2.98e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—AKT1—liver cancer	5.5e-06	2.97e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—TGFB1—liver cancer	5.5e-06	2.97e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MYC—liver cancer	5.49e-06	2.97e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—STAT3—liver cancer	5.49e-06	2.97e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—PIK3CA—liver cancer	5.49e-06	2.97e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—TGFB1—liver cancer	5.48e-06	2.96e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PIK3CD—liver cancer	5.38e-06	2.91e-05	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—AKT1—liver cancer	5.37e-06	2.9e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—PIK3CA—liver cancer	5.34e-06	2.89e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—TP53—liver cancer	5.33e-06	2.88e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—ALB—liver cancer	5.32e-06	2.87e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—TP53—liver cancer	5.31e-06	2.87e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—HRAS—liver cancer	5.28e-06	2.86e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—KRAS—liver cancer	5.27e-06	2.85e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—PIK3CA—liver cancer	5.25e-06	2.84e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—AKT1—liver cancer	5.24e-06	2.83e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—AKT1—liver cancer	5.21e-06	2.82e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—KRAS—liver cancer	5.18e-06	2.8e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—PIK3CA—liver cancer	5.18e-06	2.8e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—KRAS—liver cancer	5.17e-06	2.8e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—AKT1—liver cancer	5.17e-06	2.79e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—TP53—liver cancer	5.16e-06	2.79e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—KRAS—liver cancer	5.16e-06	2.79e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—KRAS—liver cancer	5.14e-06	2.78e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MYC—liver cancer	5.11e-06	2.76e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—HRAS—liver cancer	5.1e-06	2.76e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—TGFB1—liver cancer	5.09e-06	2.75e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—KRAS—liver cancer	5.09e-06	2.75e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—TP53—liver cancer	5.08e-06	2.75e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—KRAS—liver cancer	5.08e-06	2.75e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—HRAS—liver cancer	5.08e-06	2.74e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—IL6—liver cancer	5.06e-06	2.74e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—HRAS—liver cancer	4.94e-06	2.67e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—IL6—liver cancer	4.88e-06	2.64e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—HRAS—liver cancer	4.86e-06	2.63e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—IL6—liver cancer	4.86e-06	2.63e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—PIK3CA—liver cancer	4.84e-06	2.62e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—PIK3CA—liver cancer	4.76e-06	2.58e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—PIK3CA—liver cancer	4.75e-06	2.57e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—PIK3CA—liver cancer	4.75e-06	2.57e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—PIK3CA—liver cancer	4.74e-06	2.56e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PIK3CG—liver cancer	4.73e-06	2.56e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—IL6—liver cancer	4.72e-06	2.55e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—PIK3CA—liver cancer	4.72e-06	2.55e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—KRAS—liver cancer	4.72e-06	2.55e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PIK3CB—liver cancer	4.69e-06	2.54e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—TP53—liver cancer	4.68e-06	2.53e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—PIK3CA—liver cancer	4.68e-06	2.53e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—AKT1—liver cancer	4.67e-06	2.52e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—PIK3CA—liver cancer	4.66e-06	2.52e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—IL6—liver cancer	4.65e-06	2.51e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—AKT1—liver cancer	4.61e-06	2.5e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—TP53—liver cancer	4.61e-06	2.49e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—TP53—liver cancer	4.6e-06	2.49e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—TP53—liver cancer	4.58e-06	2.48e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—TP53—liver cancer	4.57e-06	2.47e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PPARG—liver cancer	4.56e-06	2.47e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—TP53—liver cancer	4.52e-06	2.45e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—TP53—liver cancer	4.51e-06	2.44e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—AKT1—liver cancer	4.5e-06	2.44e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—AKT1—liver cancer	4.48e-06	2.42e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—HRAS—liver cancer	4.48e-06	2.42e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—HRAS—liver cancer	4.41e-06	2.38e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—HRAS—liver cancer	4.4e-06	2.38e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—HRAS—liver cancer	4.38e-06	2.37e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—HRAS—liver cancer	4.37e-06	2.36e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—AKT1—liver cancer	4.36e-06	2.36e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—PIK3CA—liver cancer	4.33e-06	2.34e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—HRAS—liver cancer	4.33e-06	2.34e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—HRAS—liver cancer	4.32e-06	2.33e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—AKT1—liver cancer	4.29e-06	2.32e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—IL6—liver cancer	4.29e-06	2.32e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—AKT1—liver cancer	4.23e-06	2.29e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—IL6—liver cancer	4.22e-06	2.28e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—IL6—liver cancer	4.21e-06	2.28e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—IL6—liver cancer	4.2e-06	2.27e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—TP53—liver cancer	4.19e-06	2.27e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—IL6—liver cancer	4.18e-06	2.26e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PIK3CD—liver cancer	4.16e-06	2.25e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—IL6—liver cancer	4.14e-06	2.24e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—IL6—liver cancer	4.13e-06	2.23e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—ALB—liver cancer	4.1e-06	2.22e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—HRAS—liver cancer	4.01e-06	2.17e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—AKT1—liver cancer	3.95e-06	2.14e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—AKT1—liver cancer	3.89e-06	2.1e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—AKT1—liver cancer	3.88e-06	2.1e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—AKT1—liver cancer	3.88e-06	2.1e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—AKT1—liver cancer	3.87e-06	2.09e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—AKT1—liver cancer	3.86e-06	2.09e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—IL6—liver cancer	3.84e-06	2.08e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—AKT1—liver cancer	3.82e-06	2.07e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—AKT1—liver cancer	3.81e-06	2.06e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PIK3CB—liver cancer	3.62e-06	1.96e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—AKT1—liver cancer	3.54e-06	1.91e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PIK3CA—liver cancer	3.38e-06	1.83e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PIK3CA—liver cancer	2.86e-06	1.55e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—AKT1—liver cancer	2.76e-06	1.49e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—AKT1—liver cancer	2.34e-06	1.26e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PIK3CA—liver cancer	2.21e-06	1.19e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—AKT1—liver cancer	1.8e-06	9.75e-06	CbGpPWpGaD
